Safety

Company Announcement

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

INVISIBLU International LLC Issues Voluntary Nationwide Recall Of Continuum Labs Lgd-4033 Due To Product Containing LGD-4033 (Ligandrol), An Investigational Drug Not Approved For Use

For Immediate Release

April 5, 2016

Contact

Consumers

INVISIBLU INTERNATIONAL LLC
Newton Berwig
inquiry@invisiblu.net
(954) 233-2673 x1

Announcement

Invisiblu International LLC is voluntarily recalling one lot of Continuum Labs LGD-Xtreme, 3 mg to the retail and consumer level. The product has been found to contain LGD-4033 Ligandrol.

Risk Statement: The risks of using this product are unknown.  Invisiblu International has not received any reports of adverse events related to this recall.

LGD-Xtreme is marketed as a dietary supplement to promote gains of lean muscle mass. The product is packaged in a dark amber plastic bottle with ninety capsules. The affected LGD-Xtreme lot numbers are 21511166 with expiration dates of 11/2018.The product can be identified by its black label with gold trim and the Continuum Labs logo. LGD-Xtreme was sold to select end consumers in the United States via the Internet, and was exported to wholesalers in Brazil.

Invisiblu International LLC is notifying its distributors and customers by this press release and e-mail, and is asking anyone in possessing of this product to stop using and discard any unused capsules.

Consumers with questions regarding this recall can contact Invisiblu International LLC by calling (954) 233-2673, extension 1, Monday through Friday, from 9 AM to 5 PM EDT, or by sending an e-mail to: inquiry@continuum.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

###

Product Photos

  • LGD-Xtreme, Ligandrol LGD-4033, 90 Capsules

Page Last Updated: 02/12/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English